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The Immunological Basis of Dry Eye Disease
and Current Topical Treatment Options
Laura M. Periman,1 Victor L. Perez,2 Daniel R. Saban,2 Meng C. Lin,3 and Piergiorgio Neri4
Abstract
Homeostasis of the lacrimal functional unit is needed to ensure a well-regulated ocular immune response
comprising innate and adaptive phases. When the ocular immune system is excessively stimulated and/or
immunoregulatory mechanisms are disrupted, the balance between innate and adaptive phases is dysregulated
and chronic ocular surface inflammation can result, leading to chronic dry eye disease (DED). According to the
Tear Film and Ocular Surface Society Dry Eye Workshop II definition, DED is a multifactorial disorder of the
ocular surface characterized by impairment and loss of tear homeostasis (hyperosmolarity), ocular discomfort or
pain, and neurosensory abnormalities. Dysregulated ocular immune responses result in ocular surface damage,
which is a further contributing factor to DED pathology. Several therapeutics are available to break the vicious
circle of DED and prevent chronic disease and progression, including immunosuppressive agents (steroids) and
immunomodulators (cyclosporine and lifitegrast). Given the chronic inflammatory nature of DED, each of these
agents is commonly used in clinical practice. In this study, we review the immunopathology of DED and the
molecular and cellular actions of current topical DED therapeutics to inform clinical decision making.
Keywords: dry eye disease, ocular surface, inflammation, immunology, immune dysregulation, T cells, goblet cells,
integrin protein, lymphocyte function-associated antigen 1 (LFA-1), intercellular adhesion molecule 1 (ICAM-1)
Introduction
The Tear Film and Ocular Surface Society InternationalDry Eye Workshop II report defines dry eye disease
(DED) as ‘‘a multifactorial disease of the ocular surface
characterized by a loss of homeostasis of the tear film and
accompanied by ocular symptoms, in which tear film in-
stability and hyperosmolarity, ocular surface inflammation
and damage, and neurosensory abnormalities play etiologi-
cal roles.’’1 DED is believed to be progressive in some
patients.2,3 It can have significant impact on visual function,
daily activities, social and physical functions, workplace
productivity, and general quality of life.4 Global prevalence
estimates range from 5% to 50%,5 and several reports find
higher prevalence in women than in men.6–8 Additional risk
factors include increasing age,6–8 systemic comorbidities
such as diabetes and autoimmune disease,9,10 and thera-
peutic treatments for anxiety, depression, and sleep disor-
ders.11–15 The pathologic processes of chronic inflammation
and related biomarkers have been the focus of recent im-
munologic research to identify potential therapeutic tar-
gets.16 The ‘‘vicious cycle of inflammation’’ has been
proposed as a core driver in DED with the bidirectional
interaction between the ocular sensory neurons and local
immune system disrupting ocular homeostasis.16,17 Ocular
surface sensory neurons in response to inflammation can
provoke nerve impulse activity resulting in differences in
sensations, tear flow, and blinking.17 In addition, peripheral
sensory neurons can illicit an immune response by releasing
neuropeptides and immunomodulatory factors contributing to
neurogenic inflammation.17 While there are many factors
involved in DED such as/including hyperosmolarity, tear film
instability, and meibomian gland dysfunction (MGD),18,19
the purpose of this article is to explore the specific immu-
nopathogenic processes and the impact of current pharma-
cological therapies.
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Over the past 15 years, a growing body of research on the
role of inflammation in the pathogenesis of DED has led to
the recognition of dysregulation of immune responses on the
ocular surface.20 An appreciation of the basic immunolog-
ical factors associated with DED is essential for appropriate
management of patients with the disease.21 At the most
basic level, there are 2 phases of immune responses coor-
dinated to provide protection: innate and adaptive. Innate
immune responses, which occur at the ocular surface, pro-
vide a first-line generalized defense.22 Irritation, such as
environmental or endogenous factors, or microbial stress on
the ocular surface, activates signaling pathways that initiate
an acute inflammatory response, including stimulation of the
production of pro-inflammatory cytokines, matrix metallo-
proteinases (MMPs), and chemokines. The more specific
adaptive immune response is then signaled to produce
antigen-specific T cells in regional lymph nodes that migrate
to the ocular surface to respond to the ocular stressors. DED
in the chronic adaptive immunity phase is, in effect, a lo-
coregional disease. The proliferation of T cells in the
adaptive immunity phase and their amplified activation at
the ocular surface cause damage that reinitiates the acute
pro-inflammatory innate response, which, when accompa-
nied by loss of immunoregulation, triggers a vicious circle23
of pathological immune response.
Although the innate and adaptive immune responses
differ and are triggered in distinct regions, key molecular
interactions facilitating cellular migration are common to
both. The interactions between 2 cell-surface factors—
lymphocyte function-associated antigen 1 (LFA-1, an
integrin protein) and its associated ligand, intercellular
adhesion molecule 1 (ICAM-1)—are key to the proliferation
and infiltration of immune cells. Basic knowledge of their
roles in the dysregulation of ocular immunity is key to un-
derstanding current patient treatment strategies for DED.
The Ocular Surface Immune Response and DED
The ocular surface immune response involves both innate
and adaptive mechanisms.24 It occurs at the corneal surface,
in ocular tissues and regional lymph nodes, and involves T
helper (TH) cells, memory T cells, and regulatory T cells
(Tregs).25 It is a complex and tightly regulated process that
is designed to protect and defend the ocular surface but,
when dysregulated, can lead to DED.19,26–29
Specific insults or stress to the corneal surface triggers an
innate immune response on the ocular surface that is main-
tained and regulated by the corneal epithelium. Mitogen-
activated protein kinases (MAP-Ks)—specifically c-Jun
N-terminal kinase ( JNK), extracellular signal–related kinase
(ERK), and p38—are activated and stimulate transcription
nuclear factor kappa B (NF-kB), chemokines, and MMPs.30,31
A variety of immune cells reside at the ocular surface: natural
killer immune cells, dendritic cells (which are the primary
antigen-presenting cells [APCs]), macrophages, gamma delta
(gd) cells, and, to a limited extent, alpha beta (ab) T cells
(CD4+ and CD8+).26,32,33 During the innate response, specific
immune cells at the ocular surface are activated to respond to
the insult.4 Cytokines and chemokines, specifically tumor
necrosis factor alpha (TNF-a) and interleukin 1 and 6 (IL-1,
IL-6), stimulate the maturation of APCs, while chemokine
receptor 7 (CCR7) facilitates migration of mature APCs
(mAPCs) in the afferent lymphatic vessels.33,34 These mAPCs
are the primary immune cells that bridge the innate and
adaptive immune responses.33
In the adaptive immune response, mAPCs that have mi-
grated to regional lymph nodes through the afferent arm
facilitate the differentiation of naive T (TH0) cells into
several types of mature T cells, such as (1) memory T cells,
unique and specific to the antigen that caused the insult; (2)
TH cells, which become the circulating effector T cells
35;
and (3) Tregs, which modulate the immune response.33 All
of these T cells are generated in the lymph nodes and sub-
sequently migrate to the site of inflammation, the conjunc-
tiva, and the ocular surface.35–37 Although these have
seemingly contradictory functions, they all play a role in a
normal response, highlighting the multiplicities and com-
plexities of the immune system.
Memory T cells may survive in an inactive state for long
periods and proliferate upon restimulation (possibly at the
ocular surface).35,38 TH cells can be autoreactive—that is, they
can react to self-antigens.35 Once activated, they secrete pro-
inflammatory factors that sustain the immune response.27,39
Loss of homeostatic mechanisms of the lacrimal functional
unit can lead to dysregulation of the natural immune re-
sponses.40 Myriad systemic conditions are associated with loss
of homeostatic mechanisms, including hormonal abnormali-
ties, systemic and topical medications, preexisting ocular
stress, lifestyle habits, and environmental conditions.5,18,41,42
Inflammation at the ocular surface can be both a cause
and a consequence of DED.23 The resolution of inflamma-
tion at the ocular surface is usually controlled by immuno-
regulatory processes, such as goblet cell secretion of the
immunoregulatory cytokine transforming growth factor beta
(TGF-b) and programmed death-ligand 1 regulation of ac-
tivated effector T cells.35,40 When homeostatic control
mechanisms fail and immunoregulatory mechanisms such as
these are suppressed or overwhelmed, the immune response
becomes amplified, particularly the adaptive response. This
results in increased mAPC activity and increased production
and recruitment of CD4+ TH cells to the ocular surface. At
the ocular surface, the dysregulated activity of effector T
cells includes increased release of pro-inflammatory cyto-
kines, causing further inflammation and damage.39,43 This,
in turn, reinitiates the innate immune response, thus creating
a vicious circle.23 The resolution of inflammation by im-
munoregulatory processes is bypassed and/or inadequate to
address the sustained inflammation (Fig. 1).35,40
Immunopathogenesis of DED
Broken down stepwise, the immunopathogenesis of DED
is a 4-part process of initiation, amplification, recruitment,
and damage/self-perpetuation (Figs. 2 and 3). The initiation
phase of the innate immune response at the ocular surface
induces localized acute inflammation.27 Specifically, initia-
tion involves upregulation of MAP-K JNK, ERK, and p38
stimulation of NF-kB. Various pro-inflammatory mediators,
including cytokines (TNF-a, IL-1, IL-6), various inflam-
matory chemokines (CCL3, CCL4), and T cell–attracting
chemokines (CCL5, CXCL9, CXCL10), are released into
the corneal and conjunctival epithelium (Fig. 2: step 1).30,31
The release of IL-1 and TNF-a induces the activation and
maturation of APCs, which are predominantly antigen-
presenting dendritic cells (Fig. 2: step 2).34 Upregulated
ICAM-1 on lymphatic endothelial cells facilitates mAPC
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adhesion (Fig. 2: step 3).44,45 The mAPCs then migrate, in a
CCR7-mediated manner, through the efferent arm of the
ocular anatomy to regional lymph nodes (Fig. 2: step
4).46–48 The adaptive immune response involves the creation
and recruitment of effector T cells.49,50 This occurs in the
following manner: in the lymph node, mAPCs engage with
TH0 cells through an immune synapse (partly mediated by
LFA-1:ICAM-1 interaction and also T cell receptor and
major histocompatibility complex, TCR:MHC) to cause
differentiation of TH0 cells into several subsets of TH cells:
TH1, TH2,TH17, and Tregs. T cell differentiation is deter-
mined by mAPC expression of a balance of signaling fac-
tors, including IL-6, IL-12, IL-17, IL-23, TGF-b, and
interferon gamma (IFN-g) (Fig. 2: step 5).51 The proportions
and balance of the various cytokines help to drive differ-
entiation of the effector T cells into specific subtypes.
Effector T cells then migrate through the efferent arm blood
vessels to the conjunctival stroma (Fig. 2: steps 6 and 7).44,45,52–54
There, they reactivate resident mAPCs and are recruited to the
ocular surface (Fig. 2: steps 8 and 9).40 Specifically, TH1 and
TH17 are the primary lymphocyte cells involved in the ocular
surface damage and inflammation that is related to DED.35 They
release cytokines that alter the normal balance and cause epi-
thelial damage and tear dysfunction.55,56 This, in turn, elicits an
immune response and fuels the self-perpetuation cycle of DED
pathogenesis (Fig. 2: step 10).18 In nonpathogenic responses, the
Tregs are responsible for dampening the effector response and
regulating immunity.55
T cell infiltration of the lacrimal gland and conjunctiva and
amplification of the release of inflammatory cytokines are
features of chronic inflammation in DED.23,27,40,57 Pro-
inflammatory TH1 cells secrete the hallmark cytokine IFN-g,
which has been shown to promote conjunctival goblet cell loss
and apoptosis of the ocular surface epithelium.37,58 In addition,
IFN-g is associated with conjunctival squamous epithelial hy-
perplasia.37 TH17 cells secrete the hallmark cytokine IL-17 and
promote production of the MMPs from corneal epithelial cells
and fibroblasts.31,59,60 MMPs contribute to disruption of corneal
epithelial barrier function, which contributes to further ocular
insults.26 IFN-g and IL-17 also exert pathogenic effects by
promoting production of pro-inflammatory cytokines, chemo-
kines, MMPs, cell adhesion molecules, and prolymphangio-
genic molecules.40 These modulators lead to further damage of
the ocular surface and thus amplify the cycle of inflammation.
Molecular Interactions Key
to DED Pathogenesis
Integrins are cell-surface proteins expressed on a variety
of cells. They are upregulated in response to insults and also
play key roles in integrating signals among various
cells.28,54,61 The integrin LFA-1 is a leukocyte cell-surface
glycoprotein and a modulator of T cell activation and pro-
liferation.62 LFA-1 on T cells exists in an inactive or low-
affinity binding state (bent conformation), but undergoes a
conformational change to the high-affinity form of LFA-1 in
response to inflammation. Specifically, this conformational
change is due to TCR engagement in T cells and CXCR2 in
neutrophils.63 ICAM-1 is the natural ligand of LFA-1.
During inflammation, acute-phase cytokines IL-1 and TNF-
a induce upregulation of ICAM-1 expression on a variety of
cells, including the vascular endothelium of patients with
DED.36,44,64–66 Upregulation of ICAM-1 has several im-
portant functions, described further below (Fig. 2).67
FIG. 1. Ocular surface immune response. (A) A healthy system can respond to injury and invaders by mounting a
response, eliminating the pathogens while limiting tissue damage, then returning to homeostasis. (B) DED is a chronic
worsening spiral of immune response with loss of return to homeostasis (a vicious circle23 leading to damage and self-
perpetuation). DED, dry eye disease.
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The LFA-1:ICAM-1 interaction has several important
roles at key points in the immunoinflammatory pathway of
DED (Fig. 2).52 In general, binding of dendritic cells to the
vascular endothelium through LFA-1:ICAM-1 interactions
facilitates their migration to regional lymph nodes.25 LFA-
1:ICAM-1 interactions help to form the immune synapse
between mAPCs and TH0 cells, leading to T cell differen-
tiation.61 The LFA-1:ICAM-1 interaction also aids the mi-
gration of activated T cells from blood vessels to the site
of inflammation.45 LFA-1:ICAM-1 interactions are thought
to be necessary for the activation of effector T cells at the
ocular surface through the immune synapse.24 LFA-
1:ICAM-1 interactions also play a role in the recruitment of
T cells at the conjunctival epithelium and ocular surface.4
Finally, the release of cytokines and chemokines is signaled
through immune synapse/dual interactions between T cells
and mAPCs using LFA-1:ICAM-1 and TCR:MHC, respec-
tively.24,52–54 As the LFA-1:ICAM-1 interaction has a major
role in ocular surface inflammation and the ocular immune
response, treatment strategies focused on their association
have emerged as therapeutic targets.52 Whatever the pre-
cipitating cause of a patient’s DED, treatment options are
required that disrupt the chronic inflammatory process.20,21
Topical Ophthalmic Treatments for DED
Topical treatments for DED that are currently available in
the United States and Canada include immunosuppressive
agents (corticosteroids), immunomodulatory agents (cyclo-
sporine ophthalmic emulsion 0.05% and cyclosporine oph-
thalmic solution 0.09%), and the recently available LFA-1
antagonist lifitegrast ophthalmic solution 5%.68 The factors
and processes involved in DED pathology, and the DED
treatments that modulate these factors and processes, are
summarized in Figure 3.
As potent inhibitors of multiple inflammatory mediators,
topical corticosteroids are effective in interrupting the cycle
of inflammation.37 Suppression of NF-kB leads to sup-
pression of acute-phase cytokines IL-1 and TNF-a, ICAM-
1, MMPs, cytokines, chemokines, prostaglandins, and
phospholipase A.65,69,70 Topical corticosteroids also reduce
leukocyte infiltration of inflamed ocular tissues.71,72 How-
ever, known side effects (intraocular hypertension, cataracts,
decreased wound healing, and predisposition to infection)
limit their long-term use.72 KPI-121, an investigational
nanotechnology-based formulation of the corticosteroid lo-
teprednol, has been evaluated in recently completed phase 3
clinical trials for patients with DED (NCT02793817 and
NCT02813265); imminent publication of the results is ex-
pected.73
Topical cyclosporin A (CsA) is indicated to increase tear
production in patients with keratoconjunctivitis sicca.74 CsA
works by inhibiting the calcineurin–phosphatase pathway
by intracellular complex formation with cyclophilin.75 The
clinical mechanism of action of CsA has not been fully elu-
cidated,74 but it includes increased natural tear production
FIG. 3. The phases of DED pathology and its processes, effectors, and actual treatments. Color-coded symbols denote
specific DED treatment (corticosteroids, CsA, lifitegrast) modulation of DED effectors. APC, antigen-presenting cell; CCL,
CXCL, chemokines; CCR, CXCR, chemokine receptors; CD11a, cluster of designation molecule 11a; CsA, cyclosporin A;
DC, dendritic cell; DED, dry eye disease; ERK, extracellular signal–related kinase; ICAM-1, intercellular adhesion mol-
ecule 1; IFN-g, interferon gamma; IL, interleukin; JNK, c-Jun N-terminal kinase; LFA-1, lymphocyte function-associated
antigen 1; MAP-K, mitogen-activated protein kinase; mAPC, mature antigen-presenting cell; MHCII, major histocom-
patibility complex II; MMP, matrix metalloproteinase; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; NF-kB,
nuclear factor kappa B; TCR, T cell receptor; TNF-a, tumor necrosis factor alpha.
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and increased goblet cell density.38,76 The scientific litera-
ture reports numerous molecular effects of CsA on DED
immunopathophysiology, including inhibited T cell activa-
tion,74 decreased cyclophilin-mediated gene transcription of
IL-2 and IL-6,39 and decreased epithelial and goblet cell
apoptosis.77
CsA inhibits the activation of T cells as measured by
immunoactivation markers of human leukocyte antigen-D
related and cluster of designation molecule 11a (CD11a) cell
counts.76 CD11a is a subunit of LFA-1.75,78 However, T
cells that have already been activated can live for up to 164
days.79
The original phase 3 clinical trial of CsA in patients with
moderate-to-severe DED symptoms reported statistically
significant improvements in subjective symptoms (P < 0.05),
such as blurred vision, at 4 weeks. This was consistent with
the improvements seen in objective signs: in corneal stain-
ing at 4 months and categorized Schirmer values (improved
tear production) at 6 months.80 The most common side ef-
fect of CsA treatment was ocular burning.81 Other side ef-
fects included blurred vision, ocular itching, conjunctival
hyperemia, discharge, foreign body sensation, and sting-
ing.74,81 CsA ophthalmic solution 0.09%, recently approved
in the United States, also showed increased tear production
of ‡10 mm by Schirmer’s test after 12 weeks of treatment
compared with vehicle (16.8% vs. 8.6%, respectively).82
The most common adverse event was mild, moderate, or
severe instillation-site pain (the majority were mild).82
Additional side effects included conjunctival hyperemia,
blepharitis, eye irritation, headache, and urinary tract in-
fection.82 The exact molecular and cellular mechanism of
action of this new CsA concentration and formulation re-
mains to be elucidated.
Lifitegrast is approved in North America for the treatment
of the signs and symptoms of DED in adult patients.83 It is
an LFA-1 antagonist with a proposed mechanism of action
of specifically blocking the binding of ICAM-1 to LFA-1
with high affinity (Fig. 4).25 Lifitegrast has the potential to
act on both afferent and efferent arms of the immunomod-
ulatory pathway in DED.84 In the afferent arm (to the lymph
node), it may block LFA-1:ICAM-1 interaction between
dendritic cells on the ocular surface and endothelial cells of
lymphatic tissues, thereby inhibiting migration and homing
of naive dendritic cells to draining lymph nodes or activa-
tion of resting T cells at the ocular surface.25 In the efferent
arm (from the lymph node), lifitegrast may inhibit migration
of activated T cells into the conjunctiva, recruitment in
conjunctival epithelium, and secondary activation in ocu-
lar tissues.52 In experimental models, lifitegrast inhibited
IFN-g, IL-1b, IL-10, and macrophage inflammatory protein 1
alpha levels.85
A recent lifitegrast study in a murine model of desiccating
stress provided evidence of lower expression of IFN-g,
CXCL9, and TH1-related genes compared with controls.
86
FIG. 4. Effect of allosteric binding of lifitegrast to LFA-1 on LFA-1:ICAM-1 interactions. DED, dry eye disease; ICAM-
1, intercellular adhesion molecule 1; LFA-1, lymphocyte function associated antigen 1; mAPC, mature antigen-presenting
cell. Adapted from Perez et al.25
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Mice treated with lifitegrast also had less corneal barrier
disruption and greater conjunctival goblet cell density
compared with controls.86 Results of in vivo studies of lifi-
tegrast in mice and dogs have demonstrated a potent dose-
dependent inhibition of T cell activation, T cell recruitment,
and release of cytokines that has been shown to correlate
with clinical severity of DED.85,87–89 Likewise, in the
chronic allergic eye disease murine model, an immune-
mediated form of MGD is induced through a surprising
TH17 and polymorphonuclear neutrophil response and has
clinical parallels in humans.90 Subsequent studies with lifi-
tegrast treatment in this murine allergic eye disease model
resulted in reduced severity of MGD and were associated
with reduced Th17 cells and polymorphonuclear neutrophils
in the conjunctiva (Saban DR. 2019; article in preparation).
Clinical studies with lifitegrast have demonstrated im-
provements in signs and symptoms of DED.91–94 Combined
results from phase 3 efficacy and safety studies (OPUS-1,92
OPUS-2,91 and OPUS-393) and a 1-year safety study (SO-
NATA94) demonstrated that lifitegrast alleviated symptoms
of DED, with rapid onset of effect and improved signs of
DED. The most common treatment-emergent adverse event
was altered taste sensation (dysgeusia).95
Additional anti-inflammatory therapies for the treatment
of DED are under investigation. RGN-259 ophthalmic so-
lution is a synthetic copy of the naturally occurring 43
amino acid protein thymosin b4 (Tb4), which is the major
constituent protein of trauma response and wound repair cells
such as platelets, macrophages, and polymorphonuclear
cells.96 Tb4 was found to promote corneal epithelial cell mi-
gration, decrease inflammation, and accelerate epithelialization
in a murine-controlled adverse environment model of DED.97
In a phase 2 trial with RGN-259, the combined primary end
point of signs and symptoms of DED was not met.97 However,
multiple secondary end points showed improvements with
RGN-259 in the phase 2 trial and a recently completed phase 3
trial (NCT02974907).97–100
Conclusion
DED is a multifactorial disease that is characterized by a
sustained inflammatory response on the ocular surface that,
if left untreated, can lead to chronic disease. Whether DED
can be considered ‘‘progressive’’—that is, whether any
clinical characteristics of DED will progress without treat-
ment—remains to be determined. Progress in discerning the
underlying immunopathology of DED has led to advances in
treatment that target specific inflammatory effectors/path-
ways. Such treatments are needed to break the cycle of DED
and prevent chronic disease and progression.
Method of Literature Search
PubMed searches were performed and included articles
from 1987 through 2018. Terms related to dry eye (‘‘dry
eye,’’ ‘‘dry eye disease,’’ ‘‘keratoconjunctivitis sicca,’’
‘‘DED’’) and the ocular immune response (‘‘immune re-
sponse,’’ ‘‘immunopathology,’’ ‘‘pathophysiology,’’ ‘‘in-
flammation,’’ ‘‘ocular surface immune response’’) were
included. Related searches on specific ocular immune ef-
fectors, including ‘‘T cell,’’ ‘‘dendritic cell,’’ ‘‘goblet cell,’’
‘‘integrin protein,’’ ‘‘adhesion molecule,’’ ‘‘lymphocyte
function-associated antigen 1,’’ ‘‘LFA-1,’’ ‘‘intercellular
adhesion molecule 1,’’ ‘‘ICAM-1,’’ and specific topics re-
garding DED prevalence and DED-associated comorbidities
were also conducted in PubMed and Google. English
translations of abstracts were reviewed from all languages.
Articles were read from English sources. From the abstracts,
articles were reviewed that addressed areas of ocular surface
pathology, immunology, inflammation, and associated
treatments of DED.
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